AGM Results
Dublin, London | 9 May 2024
Uniphar plc (the Company) is pleased to announce that at
its Annual General Meeting held at 11.00 a.m. today, 9 May 2024,
each of the resolutions set out in the Notice of Annual General
Meeting circulated to shareholders and made available on the
Company's website, www.uniphar.ie,
were duly passed without amendment.
Details of votes cast are set out
below:
|
|
RESOLUTION
|
For
|
For %
|
Against
|
Against
%
|
Withheld
|
|
1
|
Financial Statements and
Reports
|
142,776,909
|
100
|
-
|
0
|
1,659,778
|
|
2
|
Final Dividend of €3.2m
|
144,436,687
|
100
|
-
|
0
|
-
|
|
3(a)
|
Re-elect Ger Rabbette
|
133,691,402
|
92.56
|
10,745,283
|
7.44
|
2
|
|
3(b)
|
Re-elect Tim Dolphin
|
143,757,800
|
99.53
|
678,887
|
0.47
|
-
|
|
3(c)
|
Re-elect Paul Hogan
|
143,473,422
|
99.35
|
938,265
|
0.65
|
25,000
|
|
3(d)
|
Re-elect Sue Webb
|
144,049,623
|
99.77
|
333,788
|
0.23
|
53,276
|
|
3(e)
|
Re-elect Jim Gaul
|
138,288,164
|
95.78
|
6,095,247
|
4.22
|
53,276
|
|
3(f)
|
Re-elect Liz Hoctor
|
144,320,340
|
99.94
|
91,347
|
0.06
|
25,000
|
|
3(g)
|
Re-elect Maurice Pratt
|
141,968,268
|
98.29
|
2,468,417
|
1.71
|
2
|
|
3(h)
|
Re-elect Valerie Sick
|
144,143,411
|
99.83
|
240,000
|
0.17
|
53,276
|
|
4
|
Remuneration of Auditors
|
119,304,023
|
95.49
|
5,630,519
|
4.51
|
19,502,145
|
|
5
|
Authority to allot relevant
securities
|
125,835,071
|
87.14
|
18,573,338
|
12.86
|
28,278
|
|
6
|
Disapplication of pre-emption rights
in specified circumstances
|
143,264,607
|
99.19
|
1,172,080
|
0.81
|
-
|
|
7
|
Disapplication of pre-emption rights
in additional circumstances
|
119,856,072
|
83.18
|
24,242,889
|
16.82
|
337,726
|
|
8
|
Authorise market purchases of the
Company's Ordinary Shares
|
143,853,843
|
100
|
-
|
0
|
582,844
|
|
9
|
Re-issuance of Treasury
Shares
|
142,676,687
|
98.78
|
1,760,000
|
1.22
|
-
|
--- ENDS ---
Contact Details
|
Uniphar Group
|
Tel: +353 (0) 1 428 7777
|
|
Allan Smylie, Head of
Strategy and IR
|
|
|
|
Davy (Joint Corporate Broker, Nominated Advisor
and
Euronext Growth Listing Sponsor)
|
Tel: +353 (0) 1 679 6363
|
|
Daragh O'Reilly
Niall Gilchrist
Ivan Murphy
|
|
|
|
|
|
RBC Capital Markets (Joint Corporate
Broker)
|
Tel: +44 (0) 20 7653
4000
|
|
Jamil Miah
Rupert Walford
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (Joint
Corporate Broker)
|
Tel: +44
(0) 20 7710 7600
|
|
Matt Blawat
Ben Maddison
Francis North
|
|
|
|
|
|
Q4 PR
|
Tel: +353 (0) 1 475 1444
|
|
Iarla Mongey, Public
Relations Advisor to Uniphar Group
|
|
About Uniphar plc
Headquartered in Dublin, Ireland,
the Uniphar Group is an international diversified healthcare
services business servicing the requirements of more than 200
multinational pharmaceutical and medical technology manufacturers
across three divisions - Uniphar Pharma, Uniphar Medtech and
Uniphar Supply Chain & Retail. The Group is active in Europe,
North America, APAC and MENA and delivers to 160+
countries.
The Company's vision is to improve
patient access to pharmaco-medical products and treatments by
enhancing connectivity between manufacturers and healthcare
stakeholders. Uniphar represents a strong combination of scale,
growth, and profitability.
Uniphar Supply Chain & Retail
Uniphar Supply Chain & Retail is
the leading pharmaceutical wholesaler in Ireland with a growing
symbol group offering of retail pharmacies. The Group's strategy
for Uniphar Supply Chain & Retail is to grow our wholesale
market share, our symbol group network and our own brand,
in-licenced and consumer products portfolio.
Uniphar Medtech
Uniphar Medtech is a leading
Pan-European medical device distributor and solutions partner. The
Group's strategy for Uniphar Medtech is to grow our service
offering across Europe and expand our addressable market by serving
new specialities and new manufacturers.
Uniphar Pharma
Uniphar Pharma operates a global
business with high value services across the lifecycle of a
pharmaceutical product. We enable pharma and biotech companies to
bring innovative medicines to global markets and provide healthcare
professionals with access to medicines they can't source through
traditional channels. Our strategy is to build a leading platform
to provide the specialist support and expertise needed to improve
access to these medicines.